After 40 Years, Is Vaccine For Group B Strep On Horizon?

US FDA advisory committee debates possible endpoints to demonstrate vaccine effectiveness in maternal immunization; Pfizer, which has candidate in Phase I/II study, says use of surrogate endpoint of protection may be most feasible.

Render illustration of Clinical Trial title on medical documents

For researchers looking to develop a vaccine to prevent Group B streptococcus (GBS) disease in infants, the May 17 meeting of US FDA's Vaccines and Related Biological Products Advisory Committee was a significant step forward.

The committee was asked to discuss possible endpoints to demonstrate effectiveness of GBS vaccines in preventing infant disease through maternal...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet